CY1111575T1 - ΣΥΝΔΥΑΣΜΟΣ ΕΝΟΣ ΑΝΑΣΤΟΛΕΑ ΤΟΥ ΚΟΛΠΙΚΟΥ ΡΕΥΜΑΤΟΣ If ΚΑΙ ΕΝΟΣ ΑΝΑΣΤΟΛΕΑ ΤΟΥ ΕΝΖΥΜΟΥ ΜΕΤΑΤΡΟΠΗΣ ΤΗΣ ΑΓΓΕΙΟΤΑΣΙΝΗΣ - Google Patents

ΣΥΝΔΥΑΣΜΟΣ ΕΝΟΣ ΑΝΑΣΤΟΛΕΑ ΤΟΥ ΚΟΛΠΙΚΟΥ ΡΕΥΜΑΤΟΣ If ΚΑΙ ΕΝΟΣ ΑΝΑΣΤΟΛΕΑ ΤΟΥ ΕΝΖΥΜΟΥ ΜΕΤΑΤΡΟΠΗΣ ΤΗΣ ΑΓΓΕΙΟΤΑΣΙΝΗΣ

Info

Publication number
CY1111575T1
CY1111575T1 CY20111100586T CY111100586T CY1111575T1 CY 1111575 T1 CY1111575 T1 CY 1111575T1 CY 20111100586 T CY20111100586 T CY 20111100586T CY 111100586 T CY111100586 T CY 111100586T CY 1111575 T1 CY1111575 T1 CY 1111575T1
Authority
CY
Cyprus
Prior art keywords
inhibitor
vaginal
current
converting enzyme
angiotensin converting
Prior art date
Application number
CY20111100586T
Other languages
English (en)
Inventor
Vidal Benatar
Guy Lerebours-Pigeonniere
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36685870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111575(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of CY1111575T1 publication Critical patent/CY1111575T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

Συνδυασμός ο οποίος περιέχει ένα επιλεκτικό αναστολέα και ειδικό του κολπικού ρεύματος If και πιο συγκεκριμένα την ιβαβραδίνη και ένα αναστολέα του ενζύμου μετατροπής της αγγειοτασίνης. Φάρμακα.
CY20111100586T 2005-12-21 2011-06-20 ΣΥΝΔΥΑΣΜΟΣ ΕΝΟΣ ΑΝΑΣΤΟΛΕΑ ΤΟΥ ΚΟΛΠΙΚΟΥ ΡΕΥΜΑΤΟΣ If ΚΑΙ ΕΝΟΣ ΑΝΑΣΤΟΛΕΑ ΤΟΥ ΕΝΖΥΜΟΥ ΜΕΤΑΤΡΟΠΗΣ ΤΗΣ ΑΓΓΕΙΟΤΑΣΙΝΗΣ CY1111575T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0513006A FR2894825B1 (fr) 2005-12-21 2005-12-21 Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
EP06291993A EP1800678B1 (fr) 2005-12-21 2006-12-20 Association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine

Publications (1)

Publication Number Publication Date
CY1111575T1 true CY1111575T1 (el) 2015-10-07

Family

ID=36685870

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100586T CY1111575T1 (el) 2005-12-21 2011-06-20 ΣΥΝΔΥΑΣΜΟΣ ΕΝΟΣ ΑΝΑΣΤΟΛΕΑ ΤΟΥ ΚΟΛΠΙΚΟΥ ΡΕΥΜΑΤΟΣ If ΚΑΙ ΕΝΟΣ ΑΝΑΣΤΟΛΕΑ ΤΟΥ ΕΝΖΥΜΟΥ ΜΕΤΑΤΡΟΠΗΣ ΤΗΣ ΑΓΓΕΙΟΤΑΣΙΝΗΣ

Country Status (42)

Country Link
US (2) US20070142355A1 (el)
EP (2) EP2298297A1 (el)
JP (2) JP4705564B2 (el)
KR (2) KR100907583B1 (el)
CN (1) CN101015557B (el)
AP (1) AP2119A (el)
AR (1) AR058574A1 (el)
AT (1) ATE508742T1 (el)
AU (1) AU2006252210B2 (el)
BR (1) BRPI0605517A (el)
CA (1) CA2571644C (el)
CO (1) CO5790168A1 (el)
CR (1) CR8820A (el)
CY (1) CY1111575T1 (el)
DK (1) DK1800678T3 (el)
EA (1) EA011253B1 (el)
ES (1) ES2366570T3 (el)
FR (1) FR2894825B1 (el)
GE (1) GEP20094604B (el)
GT (1) GT200600522A (el)
HK (1) HK1106444A1 (el)
HR (1) HRP20110532T1 (el)
IL (1) IL180204A (el)
JO (1) JO2699B1 (el)
MA (1) MA28723B1 (el)
ME (1) ME01958B (el)
MX (1) MXPA06014885A (el)
MY (1) MY146956A (el)
NO (1) NO337640B1 (el)
NZ (1) NZ552221A (el)
PE (2) PE20110116A1 (el)
PL (1) PL1800678T3 (el)
PT (1) PT1800678E (el)
RS (1) RS51731B (el)
SA (1) SA06270480B1 (el)
SG (2) SG173243A1 (el)
SI (1) SI1800678T1 (el)
TW (1) TWI369206B (el)
UA (1) UA86417C2 (el)
UY (1) UY30023A1 (el)
WO (1) WO2007077327A1 (el)
ZA (1) ZA200610824B (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2920772B1 (fr) * 2007-09-11 2009-10-23 Servier Lab Association entre un anti-atherothrombotique et un inhibiteur de l'enzyme de conversion de l'angiotensine
FR2927538B1 (fr) 2008-02-14 2010-02-19 Servier Lab Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant.
CN101564394B (zh) * 2008-04-21 2010-12-15 鲁南制药集团股份有限公司 含有伊伐布雷定和曲美他嗪的药物组合物
FR2961105B1 (fr) 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
WO2013116738A1 (en) * 2012-02-03 2013-08-08 Cardeus Pharmaceuticals, Inc. Drug formulations
FR3050380B1 (fr) 2016-04-20 2020-07-10 Les Laboratoires Servier Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508729A (en) * 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
DE3736866A1 (de) * 1987-10-30 1989-05-11 Thomae Gmbh Dr K Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
AU2002305809B2 (en) * 2001-06-08 2007-12-06 Ortho-Mcneil Pharmaceutical, Inc. Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
AR036187A1 (es) * 2001-07-24 2004-08-18 Adir Un proceso para la preparacion de perindopril, compuestos analogos y sus sales, compuesto intermediario 2,5-dioxo-oxazolidina y proceso para preparar un intermediario
EP1426051B1 (en) * 2001-09-11 2008-07-16 Asahi Kasei Pharma Corporation Medicinal composition for prevention of or treatment for cerebrovascular disorder
FR2834896B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'ivabradine
FR2838648B1 (fr) * 2002-04-18 2004-05-21 Servier Lab Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent
PT1362590E (pt) * 2002-07-25 2004-05-31 Boehringer Ingelheim Pharma Utilizacao de cilobradina ou dos seus sais farmaceuticamente aceitaveis para o tratamento ou prevencao de falha cardiaca
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
MA28723B1 (fr) 2007-07-02
TW200744608A (en) 2007-12-16
GEP20094604B (en) 2009-02-10
EP1800678A1 (fr) 2007-06-27
KR20070066921A (ko) 2007-06-27
KR100907583B1 (ko) 2009-07-14
PT1800678E (pt) 2011-07-12
CA2571644C (fr) 2011-03-08
JO2699B1 (en) 2013-03-03
IL180204A0 (en) 2008-01-20
SG173243A1 (en) 2011-08-29
SG133545A1 (en) 2007-07-30
IL180204A (en) 2014-02-27
HK1106444A1 (en) 2008-03-14
SA06270480B1 (ar) 2011-02-23
AP2006003859A0 (en) 2006-12-31
CR8820A (es) 2007-08-28
AR058574A1 (es) 2008-02-13
GT200600522A (es) 2007-07-25
UA86417C2 (ru) 2009-04-27
AU2006252210A1 (en) 2007-07-05
CN101015557A (zh) 2007-08-15
RS51731B (en) 2011-10-31
ME01958B (me) 2011-10-31
CN101015557B (zh) 2010-12-08
ATE508742T1 (de) 2011-05-15
AU2006252210B2 (en) 2012-04-26
KR20090047424A (ko) 2009-05-12
JP2007169283A (ja) 2007-07-05
WO2007077327A1 (fr) 2007-07-12
CO5790168A1 (es) 2007-08-31
UY30023A1 (es) 2007-01-31
US20070142355A1 (en) 2007-06-21
FR2894825B1 (fr) 2010-12-03
PE20110116A1 (es) 2011-03-02
PL1800678T3 (pl) 2011-08-31
CA2571644A1 (fr) 2007-06-21
SI1800678T1 (sl) 2011-08-31
DK1800678T3 (da) 2011-08-15
ZA200610824B (en) 2008-06-25
TWI369206B (en) 2012-08-01
ES2366570T3 (es) 2011-10-21
HRP20110532T1 (hr) 2011-08-31
PE20071004A1 (es) 2007-11-17
US20120196850A1 (en) 2012-08-02
NO337640B1 (no) 2016-05-23
EA200602155A1 (ru) 2007-08-31
JP2011079854A (ja) 2011-04-21
NZ552221A (en) 2008-05-30
BRPI0605517A (pt) 2007-10-16
EP2298297A1 (fr) 2011-03-23
MXPA06014885A (es) 2009-02-11
EA011253B1 (ru) 2009-02-27
JP4705564B2 (ja) 2011-06-22
EP1800678B1 (fr) 2011-05-11
FR2894825A1 (fr) 2007-06-22
NO20065905L (no) 2007-06-22
MY146956A (en) 2012-10-15
AP2119A (en) 2010-04-21

Similar Documents

Publication Publication Date Title
CY1111575T1 (el) ΣΥΝΔΥΑΣΜΟΣ ΕΝΟΣ ΑΝΑΣΤΟΛΕΑ ΤΟΥ ΚΟΛΠΙΚΟΥ ΡΕΥΜΑΤΟΣ If ΚΑΙ ΕΝΟΣ ΑΝΑΣΤΟΛΕΑ ΤΟΥ ΕΝΖΥΜΟΥ ΜΕΤΑΤΡΟΠΗΣ ΤΗΣ ΑΓΓΕΙΟΤΑΣΙΝΗΣ
ATE474617T1 (de) Medizinproduktsysteme
NO20044597L (no) Kjemiske forbindelser
EP1761863A4 (en) LEUMUND SYSTEM FOR ELECTRONIC MESSAGE SOURCE INFORMATION
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
TW200723527A (en) Bi-directional transistor and method therefor
AU306197S (en) Housing for electronic device
EP1847954A4 (en) INFORMATION PROVIDING DEVICE AND INFORMATION PROVIDING SYSTEM
AU306198S (en) Housing for electronic device
DE602005016976D1 (de) Informationssendevorrichtung und informationssendeverfahren
DE602004028875D1 (de) Turboladergehäuse, turbolader und multiturboladersystem
AU306199S (en) Housing for electronic device
NO20044898L (no) Nye etonogestrel estere
MX2007002277A (es) Metodos para formar retinoides y usos de los mismos.
CY1111007T1 (el) Νεος συνδυασμος ενος αναστολεα του φλεβοκομβικου ρευματος if και ενος αναστολεα ασβεστιου και φαρμακευτικες συνθεσεις που τον περιεχουν
NL1029752A1 (nl) Inrichting om stroom van een audioversterker te beperken.
DE602006010187D1 (de) Einzelsequenzhybridisierungssonden
CY1114113T1 (el) Συνδυασμος ενος αναστολεα του κολπικου ρευματος if και ενος βητα-αναστολεα
ES1061027Y (es) Dispositivo de union entre riostra y viga de encofrado.
FI20040910A0 (fi) Tekstiviestijärjestelmä
IS7441A (is) Peptíðdeformýlasatálmar
CU23732A3 (es) Nueva asociación de un inhibidor de la corriente sinusal if y de un inhibidor de la enzima de conversión
CU23733A3 (es) Composición que comprende un inhibidor selectivo de la corriente sinusal if y de un inhibidor cálcico
ITRM20020037A1 (it) Dispositivo di espositore pubblicitario con emissione acustica incorporata.
ITCR20030012A1 (it) Digestore anaerobico.